Health
A New Drug Rewrites the Rules for Resistant Lung Cancer
OptiTROP-Lung03 trial shows sacituzumab tirumotecan nearly triples progression-free survival in pretreated EGFR-mutant NSCLC
OptiTROP-Lung03 trial shows sacituzumab tirumotecan nearly triples progression-free survival in pretreated EGFR-mutant NSCLC